Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02522481 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
A Phase 3 study, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT02522481 is a Phase 3 study that has completed, run by Bracco Diagnostics. The registered enrollment target is 175 participants.
The verdict
NCT02522481, a Phase 3 study, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
Interventions
- DRUG Lumason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2018-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02522481
The ClinicalTrials.gov registry entry for NCT02522481 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumason is the first listed.
NCT02522481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02522481 about?
NCT02522481 is a clinical study titled "Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141". The purpose of this study was to assess the safety and efficacy of Lumason-enhanced dobutamine stress echo (CE-DSE) in subjects having a suboptimal left ventricular endocardial border delineation (LV EBD) at rest and who were scheduled for coronary angiography.
What is the current status of trial NCT02522481?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2015-09-24. Estimated completion is 2018-02-25.
What interventions are being tested in trial NCT02522481?
The interventions under investigation include: Lumason (DRUG).
Who is sponsoring clinical trial NCT02522481?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.